Healthcare Dec 01, 2021 05:58 PM (GMT+8) · EqualOcean
Yiouda health on December 1, Baochuan biology announced today that its independently developed bc006 monoclonal antibody injection phase I clinical trial has completed the first patient administration, in order to evaluate the safety and tolerance of the drug in the treatment of tendon sheath giant cell tumor and other advanced solid tumors. Bc006 McAb injection is a humanized IgG1 monoclonal antibody against macrophage colony stimulating factor 1 receptor (CSF-1R). Many studies have shown that the drugs targeting CSF-1R have excellent clinical benefits in the field of refractory diseases such as chronic graft-versus-host disease (cGVHD), pulmonary fibrosis (including idiopathic pulmonary fibrosis, IPF), frostbite (ALS), cystic nephropathy (PKD) and so on, in addition to giant cell tumor of tendon sheath (TGCT) and other advanced solid tumors. Up to now, no other targeted antibody drugs have entered the clinical stage in China, and the research on targeted antibody drugs abroad is still in clinical phase II.